ARS PHARMACEUTICALS, INC
NASDAQ: SPRY (ARS Pharmaceuticals, Inc.)
Kemas kini terakhir: semalam, 2:13PM5.62
-0.05 (-0.88%)
| Penutupan Terdahulu | 5.67 |
| Jumlah Dagangan | 849,460 |
| Harga / Jualan (P/S) | 9.44 |
| Harga / Buku (P/B) | 5.28 |
| Julat 52 Minggu |
| Margin Keuntungan | -16.11% |
| Margin Operasi (TTM) | -466.29% |
| EPS Cair (TTM) | -0.160 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 4,900.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 30.33% |
| Nisbah Semasa (MRQ) | 11.00 |
| Aliran Tunai Operasi (OCF TTM) | -20.48 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -9.60 M |
| Pulangan Atas Aset (ROA TTM) | -6.10% |
| Pulangan Atas Ekuiti (ROE TTM) | -6.91% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | ARS Pharmaceuticals, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -2.0 |
| Purata | 1.17 |
|
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 16.93% |
| % Dimiliki oleh Institusi | 80.28% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Tyro Capital Management Llc | 30 Jun 2026 | 4,459,337 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |